Document Detail


Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1.
MedLine Citation:
PMID:  17936447     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Human papillomavirus type 16 L1 (HPV16 L1) has shown considerable promise as a parenteral vaccine for prevention of cervical cancers. Here, we report the possibility of oral vaccination for HPV16 L1 using Lactococcus lactis (L. lactis) as a live vector. L. lactis MG1363 was transformed with two types of HPV16 L1-encoding plasmids for intracellular expression or secretion. L. lactis transformed with HPV16 L1-encoding plasmids retained biochemical lactic acid production capability. The mucosal and systemic immune responses were affected by the cellular location of expressed HPV16 L1 proteins in L. lactis. Serum IgG responses were induced after oral immunizations of L. lactis secreting HPV16 L1. Vaginal IgA immune responses were observed following oral immunization with L. lactis expressing HPV16 L1 in an intracellular form, but not with L. lactis secreting HPV16 L1. Furthermore, induction of HPV16 L1-specific mucosal immune responses was affected by immunization frequency. Six immunizations over 5 weeks were required to induce vaginal immune responses. The levels of HPV16 L1-specific vaginal IgA were maintained until 12 weeks after the first vaccination. These results suggest the feasibility of L. lactis as an oral vaccine vehicle of HPV16 L1 and demonstrate the importance of cellular loci of expressed antigen for induction of vaginal and systemic immune responses.
Authors:
Hee-Jeong Cho; Hye-Jeong Shin; In-Kwon Han; Woon-Won Jung; Young Bong Kim; Donggeun Sul; Yu-Kyoung Oh
Related Documents :
16310137 - Improving adolescent health: focus on hpv vaccine acceptance.
17627067 - Therapeutic vaccination for hpv induced cervical cancers.
14746037 - Vaccines against human papillomavirus and perspectives for the prevention and control o...
16414157 - Efficiency of hpv 16 l1/e7 dna immunization: influence of cellular localization and cap...
20637767 - The eurocine l3 adjuvants with subunit influenza antigens induce protective immunity in...
9231977 - Development of fiv-specific cytolytic t-lymphocyte responses in cats upon immunisation ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-09-29
Journal Detail:
Title:  Vaccine     Volume:  25     ISSN:  0264-410X     ISO Abbreviation:  Vaccine     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-30     Completed Date:  2007-12-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  8049-57     Citation Subset:  IM    
Affiliation:
School of Life Sciences and Biotechnology, Korea University, Anam-dong, Seongbuk-gu, Seoul 136-713, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Animals
Antibodies, Viral / blood,  immunology
Capsid Proteins / genetics,  immunology*,  metabolism*
Female
Human papillomavirus 16 / genetics,  immunology*,  metabolism*
Lactic Acid / biosynthesis
Lactococcus lactis / cytology,  genetics,  metabolism*
Mice
Mice, Inbred BALB C
Microbial Viability
Microscopy, Electron, Transmission
Mucous Membrane / immunology
Oncogene Proteins, Viral / genetics,  immunology*,  metabolism*
Plasmids / genetics
Vaccines / immunology*
Chemical
Reg. No./Substance:
0/Antibodies, Viral; 0/Capsid Proteins; 0/L1 protein, Human papillomavirus type 16; 0/Oncogene Proteins, Viral; 0/Vaccines; 50-21-5/Lactic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young ...
Next Document:  Immunogenicity of the recombinant leptospiral putative outer membrane proteins as vaccine candidates...